Allarity Therapeutics Inc (ALLR) Stock Price, Quote & News

Company Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a...

Industry: Biotechnology

Sector: Healthcare

Phone: 401 426 4664

Website: www.allarity.com

Address:

123 E. Tarpon Ave., Tarpon Springs, United States

ka1954 May. 12 at 7:50 PM

$ALLR well there goes the stock with not even a real correction in the markets. this stock will never change

1 · Reply

BULLISH1975 May. 12 at 6:49 PM

$ICU lots of catalysts incoming. Q1 quarterly tomorrow after the bell- FDA SAVE update soon. ( FDA dropped requirement from 300-50) Revenue growing- One big pediatric hospital named the Seastar SCD the new SOC- 6 breakthrough device destinations- float 4 million- about 7ish million cash-----dyor $ALLR $APVO $AMC $AGRX TAM billions SCD pediatric FDA HDE approved Phase III adult trial has a TAM or 4 billion plus. ADD TO WATCH LIST- THIS IS MY TOP HOLDING- I THINK ITS A BILLION DOLLAR COMPANY IS 2-3 YEARS device prevents organ damage- saves lives- less time in hospital- saves insurance companies money DYOR

0 · Reply

johnny6nine May. 12 at 3:35 PM

$ALLR restricted on Webull……

1 · Reply

jasonb1 May. 12 at 3:35 PM

$ALLR pull back day 🤷‍♂️

1 · Reply

Morbit1975 May. 12 at 3:19 PM

$ALLR Jensen must not have delivered the goods in Sweden.🤷‍♂️

1 · Reply

biotrade123 May. 12 at 3:10 PM

$ALLR 😭

0 · Reply

gata2016 May. 12 at 2:30 PM

$FATE Added to my position here this morning. $SLS $ALLR $AUPH

1 · Reply

johnny6nine May. 12 at 1:14 PM

$ALLR $2.34 or bust!

0 · Reply

seanolbrych May. 12 at 11:26 AM

$ALLR somethings brewing

1 · Reply

TradPoof May. 12 at 11:25 AM

$ALLR Know what you are holding, easy hold when he is $0.8s . 💪😍 Keys development- Pipeline Progress: The company is advancing Stenoparib, a PARP1/2 inhibitor, toward pivotal trials and initiating Phase 3 manufacturing.Intellectual Property: The Stenoparib DRP® test (Drug Response Predictor) received a notice of allowance from the U.S. Patent and Trademark Office in April 2026.Financial Status: In early 2026, the company closed $20 million in financing to accelerate development and support FDA approval for its oncology pipeline.

0 · Reply

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

May 5, 2026, 8:00 AM EDT - 8 days ago

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

2026-04-27T13:21:02.000Z - 15 days ago

Allarity receives notice of allowance from USPTO

Apr 27, 2026, 8:00 AM EDT - 16 days ago

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

2026-03-06T13:19:41.000Z - 2 months ago

Allarity closes $20M financing for stenoparib advancement

Mar 6, 2026, 8:00 AM EST - 2 months ago

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

2026-02-18T13:25:56.000Z - 2 months ago

Allarity doses first patients in Phase 2 trial of SCLC

Feb 18, 2026, 8:15 AM EST - 2 months ago

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

2026-02-03T13:20:33.000Z - 3 months ago

Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide

Feb 3, 2026, 8:00 AM EST - 3 months ago

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

2025-12-31T13:05:34.000Z - 4 months ago

Allarity CEO says 2026 represents an ‘inflection point’

Dec 31, 2025, 8:00 AM EST - 4 months ago

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

2025-12-03T14:15:27.000Z - 5 months ago

Allarity files $50M mixed securities shelf

2025-11-14T14:06:08.000Z - 6 months ago

Allarity reports Q3 EPS (19c) vs ($7.71) last year

Nov 14, 2025, 9:00 AM EST - 6 months ago

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

2025-09-25T21:25:29.000Z - 8 months ago

Allarity files to sell 1.56M shares of common stock for holders

2025-09-22T12:20:54.000Z - 8 months ago

Allarity presents new Phase 2 clinical data for Stenoparib

Sep 22, 2025, 8:00 AM EDT - 8 months ago

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Sep 17, 2025, 8:00 AM EDT - 8 months ago

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

2025-08-27T01:00:00.000Z - 9 months ago

Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?

2025-08-26T12:05:59.000Z - 9 months ago

Allarity announces FDA granted Fast Track designation to stenoparib

Aug 26, 2025, 8:00 AM EDT - 9 months ago

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Aug 15, 2025, 4:30 PM EDT - 9 months ago

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

2025-07-28T09:50:42.000Z - 10 months ago

Allarity initiated with a Buy at Ascendiant

Jul 15, 2025, 8:00 AM EDT - 10 months ago

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

2025-07-07T12:26:02.000Z - 11 months ago

Allarity appoints Jeff Ervin as CFO

Jul 7, 2025, 8:00 AM EDT - 11 months ago

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

2025-06-30T14:34:35.000Z - 11 months ago

Allarity gets Australian patent acceptance notice for DRP companion diagnostic

2025-06-27T12:10:38.000Z - 11 months ago

Allarity announces second patient dosed in Phase 2 trial of stenoparib

Jun 27, 2025, 8:00 AM EDT - 11 months ago

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Jun 11, 2025, 4:05 PM EDT - 11 months ago

Allarity Therapeutics Announces Changes to Board of Directors

2025-06-04T12:05:09.000Z - 1 year ago

Allarity announces research collaboration with IBRI

2025-06-02T12:30:27.000Z - 1 year ago

Allarity announces first patient enrolled in Phase 2 trial of stenoparib

May 9, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

2025-04-25T12:07:11.000Z - 1 year ago

Allarity presents poster on new data on DRP for daratumumab

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Mar 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Feb 24, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Feb 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Jan 30, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Nov 18, 2024, 8:00 AM EST - 1 year ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

ka1954 May. 12 at 7:50 PM

$ALLR well there goes the stock with not even a real correction in the markets. this stock will never change

1 · Reply

BULLISH1975 May. 12 at 6:49 PM

0 · Reply

johnny6nine May. 12 at 3:35 PM

$ALLR restricted on Webull……

1 · Reply

jasonb1 May. 12 at 3:35 PM

$ALLR pull back day 🤷‍♂️

1 · Reply

Morbit1975 May. 12 at 3:19 PM

$ALLR Jensen must not have delivered the goods in Sweden.🤷‍♂️

1 · Reply

biotrade123 May. 12 at 3:10 PM

$ALLR 😭

0 · Reply

gata2016 May. 12 at 2:30 PM

$FATE Added to my position here this morning. $SLS $ALLR $AUPH

1 · Reply

johnny6nine May. 12 at 1:14 PM

$ALLR $2.34 or bust!

0 · Reply

seanolbrych May. 12 at 11:26 AM

$ALLR somethings brewing

1 · Reply

TradPoof May. 12 at 11:25 AM

0 · Reply

biotrade123 May. 12 at 3:21 AM

$ALLR will it hold the gains tomorrow? or move up?

1 · Reply

Wody May. 12 at 2:51 AM

$ALLR

0 · Reply

ka1954 May. 11 at 7:59 PM

$ALLR shorts have gotta be nervous at this point !!!

0 · Reply

jasonb1 May. 11 at 7:42 PM

$ALLR let’s close HOD!

1 · Reply

gata2016 May. 11 at 7:27 PM

$CELH Called that. Having agreat day across the board in these others. $SLS $ALLR $AUPH

0 · Reply

RAKIN13 May. 11 at 7:11 PM

$ALLR 😍😍😍

0 · Reply

Value_Runner May. 11 at 7:02 PM

$ALLR this climb seems different than previous pops. Like it is a steady covering by the shorts who thought it would go bankrupt. They have cash on hand, a fully funded VA trial and don’t expect any additional expenses for their other trial. Short thesis seems to have disappeared.

1 · Reply